관상 동맥성 심장병 영상 진단 기기 시장 : 시장 예측(2026-2032년)

The Coronary Heart Disease Diagnostic Imaging Devices Market is projected to grow by USD 7.60 billion at a CAGR of 7.41% by 2032.

Coronary heart disease diagnostic imaging devices are central to early detection, risk stratification, treatment planning, and post-procedure assessment of ischemic heart disease. The device landscape spans noninvasive and invasive modalities, including computed tomography coronary angiography, cardiac magnetic resonance imaging, nuclear cardiology systems, echocardiography, intravascular ultrasound, optical coherence tomography, and angiography platforms used in catheterization laboratories. Demand is shaped by the global burden of cardiovascular disease, which remains the leading cause of death worldwide according to the World Health Organization, and by the clinical need to identify coronary artery stenosis, plaque burden, myocardial perfusion defects, wall motion abnormalities, and microvascular dysfunction with higher accuracy and lower procedural risk. The market environment is being influenced by guideline-driven adoption of anatomical and functional imaging, growing preference for minimally invasive diagnostics, improvements in detector technology, radiation dose reduction, point-of-care ultrasound, hybrid imaging, and digital workflow integration. Healthcare systems are also emphasizing earlier diagnosis, shorter hospital stays, and more efficient use of cath lab resources, positioning coronary heart disease diagnostic imaging devices as a strategic priority across hospitals, diagnostic centers, cardiology clinics, and ambulatory care settings.

Transformative Shifts in the Diagnostic Imaging Landscape

The coronary heart disease imaging landscape is undergoing a structural shift from single-modality, procedure-led diagnosis toward integrated, patient-specific imaging pathways. Coronary CT angiography is increasingly used to evaluate suspected coronary artery disease in appropriate low-to-intermediate risk populations, supported by improved spatial resolution, faster acquisition, and lower radiation exposure. Cardiac MRI continues to expand in myocardial viability, perfusion, fibrosis assessment, and inflammatory cardiomyopathy differentiation, while nuclear cardiology remains important for functional ischemia assessment, especially where stress testing and perfusion quantification are clinically indicated. In invasive imaging, intravascular ultrasound and optical coherence tomography are improving lesion characterization, stent optimization, and assessment of plaque morphology, strengthening the role of image-guided coronary intervention. The shift is also technological: photon-counting CT, advanced ultrasound probes, solid-state detectors, hybrid PET/CT and SPECT/CT systems, cloud-enabled image management, and interoperability standards are reshaping purchasing criteria. At the same time, value-based care is pushing providers to reduce unnecessary invasive angiography, optimize appropriateness criteria, and select imaging tools based on diagnostic yield, patient safety, workflow efficiency, and downstream clinical impact.

Cumulative Impact of Artificial Intelligence on Coronary Imaging

Artificial intelligence is creating cumulative impact across the coronary heart disease diagnostic imaging device ecosystem by improving image acquisition, reconstruction, segmentation, interpretation, reporting, and workflow prioritization. In CT and MRI, AI-enabled reconstruction can support shorter scan times, noise reduction, and dose optimization, while automated coronary calcium scoring, plaque quantification, chamber segmentation, and myocardial perfusion analysis can improve reproducibility and support consistent clinical reporting. In echocardiography, machine learning tools assist view classification, ejection fraction estimation, strain analysis, and image quality enhancement, helping address operator variability. In nuclear cardiology, AI is being applied to attenuation correction, perfusion defect detection, and risk classification, while invasive imaging platforms are increasingly integrating automated lumen and stent measurements for IVUS and OCT. The impact is not limited to diagnostics; AI-assisted triage can flag high-risk studies, streamline reading queues, and enable structured reporting linked to electronic health records. However, adoption depends on validated clinical performance, transparent algorithms, cybersecurity safeguards, data governance, regulatory clearance, integration with existing PACS and cardiovascular information systems, and clinician trust. As evidence accumulates, AI is expected to function less as a standalone feature and more as a core layer embedded within coronary imaging workflows.

Key Regional Insights Across Global Coronary Imaging Adoption

In Asia-Pacific, coronary heart disease diagnostic imaging adoption is supported by large patient populations, rising cardiometabolic risk factors, expansion of tertiary cardiac centers, and public-private investment in advanced CT, MRI, ultrasound, and cath lab infrastructure. Japan, China, India, South Korea, and Australia are prominent users of advanced cardiac imaging, while access gaps remain in rural and resource-constrained areas. Europe benefits from established cardiovascular care pathways, active adoption of radiation reduction protocols, cardiac CT and MRI expertise, and quality-focused procurement across public health systems, with differences across Western, Central, and Eastern Europe in access to newer platforms. North America is characterized by mature reimbursement structures, strong guideline adoption, advanced hospital networks, and broad use of coronary CT angiography, stress imaging, echocardiography, nuclear cardiology, and intravascular imaging for complex coronary intervention. Latin America shows growing investment in cardiology diagnostics in Brazil, Mexico, and other urban healthcare hubs, although uneven access, equipment concentration in major cities, and budget constraints influence modality selection. Africa faces the greatest access constraints, with coronary imaging availability concentrated in urban and private-sector facilities; nonetheless, increasing focus on noncommunicable disease management is improving demand for echocardiography, CT, and scalable diagnostic solutions that fit constrained infrastructure. The Middle East is advancing through investment in tertiary hospitals, specialist cardiac centers, and digital health infrastructure, particularly in higher-income Gulf economies, while broader regional access depends on workforce development and referral network maturity.

Key Group Insights Shaping Coronary Heart Disease Imaging

NATO member countries overlap with several advanced healthcare systems in North America and Europe, where procurement priorities increasingly focus on resilient supply chains, cybersecurity, digital imaging interoperability, and standardized cardiovascular care delivery across hospital networks. G7 countries generally show high utilization of evidence-based coronary imaging, broad availability of advanced modalities, and strong emphasis on AI validation, dose management, interoperability, and clinical outcomes. BRICS countries collectively represent diverse adoption conditions: China and India are expanding capacity at scale, Brazil and South Africa are addressing access disparities between public and private systems, and Russia maintains specialized cardiovascular centers with variable regional distribution of advanced imaging. The European Union provides a highly structured environment for coronary diagnostic imaging through regulatory oversight, cross-border technology standards, health technology assessment, and guideline-based care pathways that emphasize safety, appropriateness, and quality assurance. Across ASEAN, growth in coronary heart disease diagnostic imaging is influenced by rapid urbanization, expanding private healthcare networks, and national efforts to improve noncommunicable disease care, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing different levels of access to CT, MRI, nuclear cardiology, and interventional imaging. In the GCC, high cardiovascular risk profiles, strong hospital infrastructure investment, and specialist cardiac programs support adoption of advanced imaging platforms, including cardiac CT, MRI, echocardiography, and cath lab-integrated imaging.

Key Country Insights for Coronary Diagnostic Imaging Devices

China is scaling coronary imaging capacity rapidly across public hospitals and high-volume cardiac centers, supported by demand for CT, ultrasound, angiography, and increasingly AI-assisted interpretation. The United States demonstrates broad adoption of coronary CT angiography, echocardiography, nuclear cardiology, cardiac MRI, angiography, IVUS, and OCT, supported by specialized cardiac centers, established accreditation practices, and rapid AI-enabled workflow integration. Japan has longstanding strength in CT technology adoption, cardiovascular imaging research, and elderly patient care pathways, while India is expanding access through metropolitan hospital networks and diagnostic chains, with echocardiography, CT, and catheterization imaging playing major roles in coronary assessment. Germany, the United Kingdom, France, Italy, and Spain maintain strong cardiac imaging capabilities through university hospitals, specialist cardiology centers, structured clinical guidance, and established reimbursement frameworks, with growing attention to low-dose CT protocols, MRI capacity, image-guided intervention, and reducing diagnostic backlogs. Australia combines guideline-based imaging use with high-quality public and private cardiology services, and South Korea shows strong digital hospital infrastructure, advanced cath lab capabilities, and fast adoption of imaging innovation. Canada's publicly funded system emphasizes evidence-based utilization, regional cardiac imaging networks, and access optimization across provinces. Russia has advanced cardiovascular centers in major cities, though regional distribution and equipment modernization remain important factors. Brazil and Mexico are expanding advanced coronary imaging in major urban centers, with private-sector capacity often ahead of public access, while both countries face the challenge of extending timely diagnostics to wider populations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated innovation that improves diagnostic accuracy, workflow efficiency, patient safety, and integration across the coronary care pathway. Device strategies should emphasize low-dose CT imaging, faster cardiac MRI protocols, portable and AI-enabled echocardiography, quantitative nuclear cardiology, and invasive imaging tools that support precision-guided coronary intervention. Vendors and healthcare providers should strengthen interoperability with PACS, cardiovascular information systems, electronic health records, and structured reporting platforms to reduce workflow friction. AI deployment should be supported by transparent validation, bias assessment, post-market monitoring, cybersecurity controls, and clinician training. For emerging markets, scalable solutions such as robust ultrasound systems, optimized CT protocols, remote reading networks, and service models that reduce downtime can improve adoption. Procurement teams should evaluate total cost of ownership, uptime, service coverage, regulatory compliance, dose management, data security, and compatibility with existing infrastructure. Clinical leaders should align imaging selection with evidence-based appropriateness criteria, multidisciplinary heart team workflows, and measurable outcomes such as reduced unnecessary invasive angiography, faster diagnosis, and improved treatment planning.

Research Methodology for Evidence-Based Imaging Insights

This executive summary is developed using a secondary research-led methodology grounded in verified public-domain and industry-relevant sources. The approach includes review of clinical guidelines, regulatory documentation, peer-reviewed cardiology and radiology literature, public health datasets, technology assessment reports, hospital imaging practice trends, and authoritative cardiovascular disease references. Insights were synthesized across modality categories, including CT, MRI, ultrasound, nuclear imaging, angiography, intravascular ultrasound, and optical coherence tomography, with attention to clinical use cases, technology innovation, regional healthcare infrastructure, and adoption barriers. Regional and country-level interpretations were derived from documented healthcare system characteristics, disease burden indicators, imaging access patterns, reimbursement environments, and digital health readiness. The analysis avoids market sizing, market share, and forecasting, focusing instead on evidence-backed qualitative assessment of industry dynamics, clinical utility, technology shifts, and strategic implications for coronary heart disease diagnostic imaging devices.

Conclusion: Future Direction of Coronary Heart Disease Imaging

Coronary heart disease diagnostic imaging devices are becoming more precise, connected, and clinically integrated as healthcare systems seek earlier diagnosis, better risk stratification, and more efficient treatment pathways. Advances in cardiac CT, MRI, echocardiography, nuclear imaging, angiography, IVUS, OCT, and AI-enabled analytics are reshaping how clinicians detect coronary artery disease, assess ischemia, characterize plaque, and guide intervention. Adoption varies significantly by region, with mature systems focusing on optimization and digital integration, while emerging systems prioritize access, affordability, workforce capacity, and infrastructure resilience. The strongest opportunities for industry progress lie in validated AI, low-dose and high-throughput imaging, interoperable platforms, scalable service models, and imaging pathways aligned with evidence-based cardiovascular care. Organizations that combine clinical credibility, regulatory discipline, digital security, and workflow-centered innovation will be best positioned to support the next generation of coronary heart disease diagnosis.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Coronary Heart Disease Diagnostic Imaging Devices Market, by Device Type

• 7.1. Introduction
• 7.2. Invasive Imaging Devices
  • 7.2.1. Intravascular Ultrasound (IVUS) Systems
  • 7.2.2. Optical Coherence Tomography (OCT) Systems
  • 7.2.3. Fractional Flow Reserve (FFR) Imaging Systems
  • 7.2.4. Near-Infrared Spectroscopy (NIRS) Systems
• 7.3. Non-Invasive Imaging Devices

8. Coronary Heart Disease Diagnostic Imaging Devices Market, by Technology

• 8.1. Introduction
• 8.2. X-ray Based Imaging
• 8.3. Ultrasound-Based Imaging
• 8.4. Magnetic Resonance Technology
• 8.5. Nuclear Imaging Technology
• 8.6. Optical Imaging

9. Coronary Heart Disease Diagnostic Imaging Devices Market, by Portability

• 9.1. Introduction
• 9.2. Fixed Imaging Systems
• 9.3. Mobile Imaging Systems
• 9.4. Portable Handheld Devices

10. Coronary Heart Disease Diagnostic Imaging Devices Market, by Application

• 10.1. Introduction
• 10.2. Diagnosis of Coronary Artery Disease
• 10.3. Pre-operative Planning
• 10.4. Post-operative Monitoring
• 10.5. Risk Assessment
• 10.6. Emergency Cardiac Care

11. Coronary Heart Disease Diagnostic Imaging Devices Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Care Centers
• 11.3. Diagnostic Centers
• 11.4. Hospitals
• 11.5. Specialty Clinics

12. Coronary Heart Disease Diagnostic Imaging Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Coronary Heart Disease Diagnostic Imaging Devices Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Coronary Heart Disease Diagnostic Imaging Devices Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Arineta Ltd.
• 16.3. Boston Scientific Corporation
• 16.4. Bracco Imaging S.p.A.
• 16.5. Canon Medical Systems Corporation
• 16.6. Cardinal Health, Inc.
• 16.7. Carestream Health, Inc.
• 16.8. Edwards Lifesciences Corporation
• 16.9. Esaote S.p.A.
• 16.10. FUJIFILM Holdings Corporation
• 16.11. GE HealthCare Technologies Inc.
• 16.12. Hitachi, Ltd.
• 16.13. Hologic, Inc.
• 16.14. Johnson & Johnson Services
• 16.15. Konica Minolta, Inc.
• 16.16. Koninklijke Philips N.V.
• 16.17. Medtronic plc
• 16.18. Mindray Bio-Medical Electronics Co., Ltd.
• 16.19. Neusoft Medical Systems Co., Ltd.
• 16.20. Positron Corporation
• 16.21. Samsung Medison Co., Ltd.
• 16.22. Shimadzu Corporation
• 16.23. Siemens Healthineers AG
• 16.24. United Imaging Healthcare Co., Ltd.